- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mo | EMA advisors say CSL's Tavneos should be pulled from sale | ||
| 26.06. | Sanofi faces EU investigation over flu shot marketing | ||
| 26.06. | Moderna shows in vivo CAR-T hand in R&D update | ||
| 26.06. | Obesity is rising fastest in young adults in England | ||
| 25.06. | Merck buys life sciences firm Bio-techne in $11.3bn deal | ||
| 25.06. | Hub-and-spoke firm Osanni raises $190m, and other financings | ||
| 25.06. | Ibrance cleared in US for 'double-positive' breast cancer | ||
| 25.06. | Tarek Samad takes on task of delivering on Lundbeck's R&D | ||
| 25.06. | NICE delivers more good news for cervical cancer patients | ||
| 25.06. | Ionis' Tryngolza claims critical label expansion in US | ||
| 25.06. | Lilly launches its LillyDirect sales channel in the UK | ||
| 24.06. | NICE says Libtayo can be used for advanced cervical cancer | ||
| 24.06. | Bispecific antibody firm Ollin raises $330m in bumper round | ||
| 24.06. | Astellas Padcev and Gilead's Trodelvy grab key EU approvals | ||
| 24.06. | UK's RQ Bio raises $115m for flu prevention drug | ||
| 24.06. | EFPIA report adds to pressures on EU drug pricing policy | ||
| 23.06. | HHS details plan to regain the US's edge in clinical trials | ||
| 23.06. | Pfizer's Seagen-derived ADC pipeline suffers a setback | ||
| 23.06. | MSD's TL1A drug tulisokibart delivers in pivotal IBD trial | ||
| 23.06. | Sanofi's type 1 diabetes-delaying drug cleared for NHS use | ||
| 22.06. | CARSgen bags world-first approval for solid tumour CAR-T | ||
| 22.06. | AbbVie climbs post-Allergan M&A peak with Apogee buy | ||
| 22.06. | Boehringer advances duo for aggressive cancers into phase 3 | ||
| 22.06. | Genpact finds $18tn in trapped AI value | ||
| 22.06. | Insilico and SK Bio forge $2.5bn AI neuroimmunity alliance |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.